Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 1 open reading frame 226 (C1orf226) encodes a protein of currently unknown function and is classified as an uncharacterized protein-coding gene. It is mapped to human chromosome 1 and has two known protein-coding transcript variants. C1orf226 has been associated, through genomic studies, with rare disease contexts, including phosphoglycerate dehydrogenase deficiency and nephrotic syndrome, but evidence for a direct causal role remains limited. In neurological studies, it is among a small group of genes whose regulation appears modified in response to TDP-43 knockdown, suggesting indirect or downstream roles in neurodegenerative conditions such as amyotrophic lateral sclerosis, though no direct function or therapeutic relevance has been established. There are no data supporting its classification as a therapeutic target, receptor, or enzyme. Currently, C1orf226 remains a gene of unknown function, requiring further research for full biological and clinical characterization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 1 open reading frame 226 (C1orf226).